Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 April 2000Website:
http://www.lexpharma.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 18:38:24 GMTDividend
Analysts recommendations
Institutional Ownership
LXRX Latest News
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will be holding its Q1 2024 Earnings Conference Call on May 2, 2024 at 5:00 PM ET. Company representatives present include Lisa DeFrancesco, Lonnel Coats, Jeffrey Wade, Craig Granowitz, Tom Garner, and Alan Main. Conference call participants include John Geelan, Roanna Ruiz, Andrew Tsai, and Joseph Stringer. The call will focus on the company's first quarter 2024 financial results. Participants are currently in a listen-only mode.
Lexicon Pharmaceuticals (LXRX) reported a quarterly loss of $0.20 per share, slightly higher than the Zacks Consensus Estimate of a loss of $0.18 per share. This is an increase from the loss of $0.17 per share reported in the same quarter last year.
Lexicon (LXRX) could see an increase in value due to increased confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.
- 1(current)
What type of business is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
What sector is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals is in the Healthcare sector
What industry is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals is in the Biotechnology industry
What country is Lexicon Pharmaceuticals from?
Lexicon Pharmaceuticals is headquartered in United States
When did Lexicon Pharmaceuticals go public?
Lexicon Pharmaceuticals initial public offering (IPO) was on 07 April 2000
What is Lexicon Pharmaceuticals website?
https://www.lexpharma.com
Is Lexicon Pharmaceuticals in the S&P 500?
No, Lexicon Pharmaceuticals is not included in the S&P 500 index
Is Lexicon Pharmaceuticals in the NASDAQ 100?
No, Lexicon Pharmaceuticals is not included in the NASDAQ 100 index
Is Lexicon Pharmaceuticals in the Dow Jones?
No, Lexicon Pharmaceuticals is not included in the Dow Jones index
When does Lexicon Pharmaceuticals report earnings?
The next expected earnings date for Lexicon Pharmaceuticals is 02 August 2024